Guardant Health, Inc. ( GH) Stock. Should you Buy or Sell? $ 59.28
1.30 (2.15 %)
Guardant Health, Inc. Analysis
Updated on 10-09-2022| Symbol | GH |
| Price | $59.28 |
| Beta | 0.799 |
| Volume Avg. | $1.03 M |
| Market Cap | $6.06 B |
| 52 Week Range | $27.65 - $132.87 |
Guardant Health, Inc. opened the day at $59.28 which is +'2.15 % on yesterday's close. Guardant Health, Inc. has a 52 week high of $132.87 and 52 week low of $27.65, which is a difference of $105.22. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $6.06 B and total net profit is $373653000 which means the company is trading at 16.22 times profit to market capitalization. Theoretically, if you were to buy Guardant Health, Inc. for $6.06 B, it would take 15 years to get your money back. Guardant Health, Inc. are in the Diagnostics & Research space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Guardant Health, Inc. Stock Forecast - Is Guardant Health, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Strong Buy | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -10.977 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.350 |
Valuing Guardant Health, Inc.
| Price Book Value Ratio | 18.958 | Price To Book Ratio | 18.958 |
| Price To Sales Ratio | 14.822 | Price Earnings Ratio | -10.977 |
How liquid is Guardant Health, Inc.
| Current Ratio | 6.182 |
| Quick Ratio | 5.657 |
Debt
| Debt Ratio | 0.828 | Debt Equity Ratio | 4.810 |
| Long Term Debt To Capitalization | 0.810 | Total Debt To Capitalization | 0.812 |
Latest news about Guardant Health, Inc.
The company deepened its relationship with an important peer.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York. Guardant Health's management is scheduled to participate in a fireside chat on Monday, September 12th at 8:10 a.m. Eastern Time / 5:10 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section o
Investors are cheered by the company's latest set of quarterly results, in spite of a deeper net loss.
Guardant Health, Inc. (NASDAQ:GH ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jack Meehan - Nephron Research Mark Massaro - BTIG Brian Weinstein - William Blair Kyle Mikson - Canaccord Matt Sykes - Goldman Sachs Daniel Macek - Stifel David Westenberg - Piper Sandler Derik De Bruin - Bank of America Patrick Donnelly - Citi Operator Hello and welcome to today's Guardant Health Second Quarter 2022 Financial Results. My name is Bailey, and I will be your moderator for today's call.
Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
About Guardant Health, Inc.
Description :
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
